Publikace

Souhrn publikací našich původních prací či ve spolupráci od roku 2011.

2024

Belohlavkova P, Zackova D, Klamova H, Faber E, Karas M, Stejskal L, Cmunt E, Cerna O, Jeziskova I, Machova Polakova K, Zak P, Jurkova T, Chrapava M, Mayer J. Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data. Cancer Med. 2024 Sep;13(17):e70158. doi: 10.1002/cam4.70158. PMID: 39267544; PMCID: PMC11393449.

Burda P, Hlavackova A, Polivkova V, Curik N, Laznicka A, Krizkova J, Suttnar J, Klener P, Polakova KM. Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events. Mol Metab. 2024 Oct;88:102016. doi: 10.1016/j.molmet.2024.102016. Epub 2024 Aug 23. PMID: 39182842; PMCID: PMC11403060.

Hovorkova L, Winkowska L, Skorepova J, Krumbholz M, Benesova A, Polivkova V, Alten J, Bardini M, Meyer C, Kim R, Trahair TN, Clappier E, Chiaretti S, Henderson M, Sutton R, Sramkova L, Stary J, Polakova KM, Marschalek R, Metzler M, Cazzaniga G, Cario G, Trka J, Zaliova M, Zuna J. Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients. Mol Cancer. 2024 Jul 5;23(1):138. doi: 10.1186/s12943-024-02053-4. PMID: 38970095; PMCID: PMC11229488.

Dolnikova A, Kazantsev D, Klanova M, Pokorna E, Sovilj D, Kelemen CD, Tuskova L, Hoferkova E, Mraz M, Helman K, Curik N, Machova Polakova K, Anděra L, Trněný M, Klener P. Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status. Blood Adv. 2024 May 7:bloodadvances.2024012906. doi: 10.1182/bloodadvances.2024012906. Epub ahead of print. PMID: 38713893.

Curik N, Laznicka A, Polivkova V, Krizkova J, Pokorna E, Semerak P, Suchankova P, Burda P, Hochhaus A, Machova Polakova K. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations. Leukemia. 2024 Jun;38(6):1415-1418. doi: 10.1038/s41375-024-02248-0. Epub 2024 Apr 13. PMID: 38615117; PMCID: PMC11147753.

Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647. Epub ahead of print. PMID: 38471049.

Žáčková D, Semerád L, Faber E, Klamová H, Stejskal L, Bělohlávková P, Karas M, Cmunt E, Černá O, Procházková J, Čičátková P, Kvetková A, Horňák T, Skoumalová I, Srbová D, Šálek C, Buffa D, Voglová J, Jurček T, Folta A, Ježíšková I, Žižková H, Machová Poláková K, Papajík T, Žák P, Jindra P, Svobodník A, Štěpánová R, Mayer J. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia. 2024 Mar 12. doi: 10.1038/s41375-024-02215-9. Epub ahead of print. PMID: 38472478.

Benesova A, De Santis S, Polivkova V, Pecherkova P, Krizkova J, Suchankova P, Monaldi C, Klamova H, Srbova D, Zizkova H, Hochhaus A, Soverini S, Machova Polakova K. Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia. Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27232. Epub ahead of print. PMID: 38314531.

Hornak T, Mayer J, Cicatkova P, Semerad L, Kvetkova A, Klamova H, Faber E, Belohlavkova P, Karas M, Stejskal L, Cmunt E, Cerna O, Srbova D, Zizkova H, Vrablova L, Skoumalova I, Voglova J, Jurkova T, Chrapava M, Jurcek T, Jeziskova I, Jarosova M, Machova Polakova K, Papajik T, Zak P, Jindra P, Zackova D. De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27229. Epub ahead of print. PMID: 38317312.

2023 

Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4. PMID: 37794101; PMCID: PMC10624636.

Machova Polakova K, Albeer A, Polivkova V, Krutska M, et al. The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02109-2. Epub ahead of print. PMID: 38129513.

2022

Salmon, M., White, H.E., Zizkova, H. … Machova Polakova K, Cross NCP et al. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia (2022). doi.org/10.1038/s41375-022-01612-2

White, H.E., Salmon, M., Albano, F. … Zizkova H. … Machova Polakova K, Hochhaus A, Cross NCP et al. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia (2022). doi.org/10.1038/s41375-022-01607-z

Soverini S, De Santis S, Martelli M, Monaldi C, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Bruno S, Venturi C, Machova Polakova K, Ernst T, Maar D, Corner A, Cavo M. Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia. Leukemia. 2022 Jul 30. doi: 10.1038/s41375-022-01660-8. Epub ahead of print. PMID: 35908105.-8

2021

Curik N, Polivkova V, Burda P, Koblihova J, Laznicka A, Kalina T, Kanderova V, Brezinova J, Ransdorfova S, Karasova D, Rejlova K, Bakardjieva M, Kuzilkova D, Kundrat D, Linhartova J, Klamova H, Salek C, Klener P, Hrusak O and Machova Polakova K (2021) Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining. Front. Oncol. 11:744373. doi: 10.3389/fonc.2021.744373

Scott S, Cartwright A, Francis S, Whitby L, Sanzone AP, Mulder A, Galimberti S, Dulucq S, Mauté C, Lauricella C, Salmon M, Rose S, Willoughby J, Boeckx N, Pallisgaard N, Maier J, Leibundgut EO, Zizkova H, Ling Goh L, Duong C, Tang WF, Ma E, Shivakumar Y, Beppu L, Bhagavatula P, Chantry A. Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study. Br J Haematol. 2021 Jul;194(1):53-60. doi: 10.1111/bjh.17521. Epub 2021 Jun 10. PMID: 34114218.

Polivkova V, Benesova A, Zizkova H, Koblihova J, Curik N, Motlova E, Klamova H, Salek C, Machova Polakova K Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells Leukemia 2021 Mar 26. doi:10.1038/s41375-021-01226-0

Schäfer V, White HE, Gerrard G, Möbius S, Saussele S, Franke GN, Mahon FX, Talmaci R, Colomer D, Soverini S, Machova Polakova K, Cross NCP, Hochhaus A, Ernst T Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. Journal of Cancer Research and Clinical Oncology 2021 Mar 7. doi: 10.1007/s00432-021-03569-8

2020

Hrdinova T, Toman O, Dresler J, Klimentova J, Salovska B, Pajer P, Bartos O, Polivkova V, Linhartova J, Machova Polakova K, Kabickova H, Brodska B, Krijt M, Zivny J, Vyoral D, Petrak J. Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib. Int J Oncol (2020) Dec 23. doi: 10.3892/ijo.2020.5163. Online ahead of print.

Čuřík N., Koblihová J. Vzdělávací workshop – uplatnění nových technologií v precizní medicíně CML a ALL. Transfuze a hematologie dnes 26 (2020), číslo 1, str. 66-69.

Machova Polakova, K., Zizkova, H., Zuna, J. et al. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia (2020).  doi: 10.1038/s41375-020-0882-1

SILVESTRI, G.; TROTTA, R.; STRAMUCCI, L.; ELLIS, J.J.; HARB, J.G.; NEVIANI, P.; WANG, S.; EISFELD, A.-K.; WALKER, C.J.; ZHANG, B.; SRUTOVA, K.; GAMBACORTI-PASSERINI, C.; PINEDA, G.; JAMIESON, C.H.M.; STAGNO, F.; VIGNERI, P.; NTELIOPOULOS, G.; C. MAY, P.C.; REID, A.G.; GARZON, R.; ROY, D.-C.; MOUTUOU, M.M.; GUIMOND, M.; HOKLAND, P.; DEININGER, M.W.; FITZGERALD, G.; HARMAN, C.; DAZZI, F.; MILOJKOVIC, D.; APPERLEY, J.F.; MARCUCCI, G.; QI, J.; MACHOVA POLAKOVA, K.; ET AL. Persistence of drug-resistant leukemic stem cells and impaired NK cell immunity in CML patients depend on MIR300 antiproliferative and PP2A-activating functions. Blood cancer discovery. 2020, vol. 1, no. 1, s. 1-20. ISSN 2643-3230.

2019

Čuřík N., Sympozium G3 2019 – „Umělá inteligence – budoucnost onko-hematologie“. Transfuze a hematologie dnes 25 (2019), číslo 2, str. 197-199.

Burda P., Methylace DNA – vyšší princip genetické informace jako cesta k léčbě MDS. Myelodysplastic Syndrome News 7 (2019), číslo 2, str. 5-11.

K. Machová Poláková; N. Čuřík; H. Votavová; J. Trka. 25 let vývoje metod molekulární biologie a jejich uplatnění v hemato(onko)logii. Transfuze Hematol. dnes,25, 2019, No. 1, p. 34-42.

Möbius S, Schenk T, Himsel D, Maier J, Franke GN, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, Cross NCP, Hochhaus A, Ernst T. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). J Cancer Res Clin Oncol. 2019 Apr 2. doi: 10.1007/s00432-019-02910-6. [Epub ahead of print]

2018

Čuřík N. G3 Sympozium 2018 – Remise bez nutnosti terapie (TFR) u chronické myeloidní leukemie. Transfuze a hematologie dnes 24 (2018), číslo 3, str. 222-224.

Koblihova J, Srutova K, Krutska M, Klamova H, Machova Polakova K. AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome. PLoS One. 2018 Nov 8;13(11):e0206620. doi: 10.1371/journal.pone.0206620. eCollection 2018.

Musilova K, Devan J, Cerna K, Seda V, Pavlasova G, Sharma S, Oppelt J, Pytlik R, Prochazka V, Prouzova Z, Trbusek M, Zlamalikova L, Liskova K, Kruzova L, Jarosova M, Mareckova A, Kornauth C, Simonitsch-Klupp I, Schiefer AI, Merkel O, Mocikova H, Burda P, Machova Polakova K, Kren L, Mayer J, Zent CS, Trneny M, Evans AG, Janikova A, Mraz M. miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. Blood. 2018 Sep 13. pii: blood-2018-06-855502. doi: 10.1182/blood-2018-06-855502.

Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Machova Polakova K. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Haematologica. 2018 Jul 26. pii: haematol.2018.193086. doi: 10.3324/haematol.2018.193086.

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V1, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018 May 4. pii: S1470-2045(18)30192-X. doi: 10.1016/S1470-2045(18)30192-X.

2017

Jaruskova M, Curik N, Hercog R, Polivkova V, Motlova E, Benes V, Klamova H, Pecherkova P, Belohlavkova P, Vrbacky F, Machova Polakova K. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment. J Exp Clin Cancer Res. 2017 Apr 18;36(1):55. doi: 10.1186/s13046-017-0523-3.

Lenka Hovorkova, Marketa Zaliova, Nicola C. Venn, Kirsten Bleckmann, Marie Trkova, Eliska Potuckova, Martina Vaskova, Jana Linhartova, Katerina Machova Polakova, Eva Fronkova, Walter Muskovic, Jodie E. Giles, Peter J. Shaw, Gunnar Cario, Rosemary Sutton, Jan Stary, Jan Trka and Jan Zuna. Monitoring of childhood ALL using _BCR-ABL1_ genomic breakpoints identifies a subgroup with CML-like biology. Blood. 2017: blood-2016-11-749978; doi: https://doi.org/10.1182/blood-2016-11-749978

2016

Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. BMC Cancer. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0

Toman O, Kabickova T, Vit O, Fiser R, Polakova KM, Zach J, Linhartova J, Vyoral D, Petrak J. Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target. Oncol Rep. 2016 Sep;36(3):1258-68. doi: 10.3892/or.2016.4945. Epub 2016 Jul 18

Zemanová K., Žižková H., Jurček T., Dvořáková D., Zach J., Polívková V., Vlčanová K., Divoká M., Křupková L., Hrochová K., Karas M., Machová Poláková K. Chronická myeloidní leukemie – standardizace molekulárního monitorování hladiny transkriptů BCR-ABL1 v České republice. Transfuze Hematol. Dnes, 22, 2016, No. 1, p. 56-64

Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S. Development and evaluation of a secondary reference panel for BCR-ABL1 quantitation on the International Scale. Leukemia. 2016 Apr 25. doi: 10.1038/leu.2016.90. [Epub ahead of print]

Preuner S, Barna A, Frommlet F, Czurda S, Konstantin B, Alikian M, Machova Polakova K, Sacha T, Richter J, Lion T, Gabriel C. Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches. Int J Mol Sci. 2016 Apr 29;17(5). pii: E642. doi: 10.3390/ijms17050642.

Polivkova V, Rohon P, Klamova H, Cerna O, Divoka M, Curik N, Zach J, Novak M, Marinov I, Soverini S, Faber E, Machova Polakova K. Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. PLoS One. 2016 May 23;11(5):e0155959. doi: 10.1371/journal.pone.0155959. eCollection 2016.

Soverini S, De Benedittis C, Papayannidis C, Machova Polakova K, Venturi C, Russo D, Bresciani P, Iurlo A, Mancini M, Vitale A, Chiaretti S, Foà R, Abruzzese E, Sorà F, Kohlmann A, Haferlach T, Baccarani M, Cavo M, Martinelli G. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. Leukemia. 2016 Feb 12. doi: 10.1038/leu.2016.17. [Epub ahead of print]

Soverini S, De Benedittis C, Machova Polakova K, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, Martinelli G. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. Oncotarget. 2016 Mar 9. doi: 10.18632/oncotarget.8010. [Epub ahead of print]

2015

Linhartova J, Hovorkova L, Soverini S, Benesova A, Jaruskova M, Klamova H, Zuna J, Machova Polakova K. Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing. Mol Cancer. 2015 Apr 18;14:89. doi: 10.1186/s12943-015-0363-8.

Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015 May;29(5):999-1003.

Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, de Benedittis C, Haferlach T, Baccarani M, Martinelli G, Stopka T, Ernst T, Hochhaus A, Kohlmann A, Soverini S. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015 May;141(5):887-99.

2014

Simona Soverini , Caterina De Benedittis , Katerina Machova Polakova , Gianantonio Rosti , Michele Baccarani and Giovanni Martinelli. BCR-ABL1 compound mutants in Philadelphia chromosome-positive (Ph+) leukemias: hot or not?  E-letter to July 3, 2014; Blood: 124 (1).

White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikienė E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, et al. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. Leukemia. 2014 Jul 18. doi: 10.1038/leu.2014.217. [Epub ahead of print].

2013

Machova Polakova K, Koblihova J, Stopka T. Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep. 2013 Mar;8(1):28-36.

Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, et al.Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013 Aug 29;122(9):1634-48.

Pavlík, T.; Janoušová, E.; Mayer, J.; Indrák, K.; Jarošová, M.; Klamová, H.; Žáčková, D.; Voglová, J.; Faber, E.; Karas, M.; Machová Poláková, K.; et al.. Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications. American journal of hematology. 2013, vol. 88, no. 9, s. 790-797.

Žáčková, D.; Klamová, H.; Mužík, J.; Cmunt, E.; Ráčil, Z.; Machová Poláková, K.; Dvořáková, D.; Jurček, T.; Rázga, F.; Cetkovský, P.; Dušek, L.; Mayer, J. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for chronic myeloid leukemia patients treated in three different hospitals compare well with results achievable in formal clinical trials. Leukemia & lymphoma. 2013, vol. 54, no. 10, s. 2310-2313.

Klamová H, Poláková KM, Mužík J, Ráčil Z, Záčková D, et al. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels. Cancer Med. 2013 Apr;2(2):216-25.

2012

Kramarzová, K.; Stuchlý, J.; Willasch, A.; Gruhn, B.; Schwarz, J.; Čermák, J.; Machová Poláková, K.; Fuchs, O.; Starý, J.; Trka, J.; Boublíková, L. Real-time PCR quantification of major Wilms’ tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences. Leukemia. 2012, vol. 26, no. 9, s. 2086–2095.

Machová Poláková K, Zemanová K, Součková M, Broučková A, Klamová H. Molekulární genetika v diagnostic a léčbě chronické myeloidní leukémie.  Vnitr Lek. 2012 Aug;58 Suppl 2:38-45.

Slabý O., Svoboda M, .et al. MikroRNA v onkologii:  Machová Poláková K. MikroRNA u chronické myeloidní leukemie. str.243-252. 2012, Galén, ISBN 978-80-7262-587-1.

2011

Kateřina Machová Poláková, Tereza Lopotová, Hana Klamová, Pavel Burda, Marek Trněný, Tomáš Stopka, Jana Moravcová. Expression pattern of microRNAs associated with CML phases and disease related targets. Molecular Cancer  2011, 10:41.

F. Razga, Z. RacilZ, K. Machova Polakova, L.  Buresova, H. Klamova, D.  Zackova , D. Dvorakova, V. Polivkova, P. Cetkovsky, J. Mayer. The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia. Int J Hematol. 2011 Sep;94(3):303-6.

Zdenek Racil, Filip Razga, Katerina Machova Polakova, Lucie Buresova, Vaclava Polivkova, Dana Dvorakova, Daniela Zackova, Hana Klamova, Petr Cetkovsky, Marek Trneny, Jiri Mayer. Assessment of the ATP-binding cassette sub-family B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia:  the role of different cell types. Leuk and Lymph, 2011:52(2):331-334.

Daniela Zackova, Hana Klamova, Ladislav Dusek, Jan Muzik, Katerina Machova Polakova, Jana Moravcova, Tomas Jurcek, Dana Dvorakova, Zdenek Racil, Zdenek Pospisil, Alexandra Oltova, Kyra Michalova, Jana Brezinova, Filip Razga, Michael Doubek, Petr Cetkovsky, Marek Trneny, and Jiri Mayer. Imatinib as the First Line Treatment of Patients with Chronic Myeloid Leukemia Diagnosed in the Chronic Phase: Can We Compare Real Life Data to the Results from Clinical Trials? Am J Hematol. 2011 Mar;86(3):318-21.